J Korean Epilepsy Soc.
2000 Jun;4(1):27-29.
Efficacy of Topiramate in West Syndrome
- Affiliations
-
- 1Department of Pediatrics, Inha University College of Medicine, Inchon, Korea.
- 2Department of Pediatrics, Eulji University College of Medicine, Daejeon, Korea.
- 3Department of Pediatrics, ISeoul National University College of Medicine, Seoul, Korea. pednr@plaza.snu.ac.kr
Abstract
-
PURPOSE: The treatment of West syndrome is difficult since current antiepileptic drugs are rarely effective. The objective of this study is to evaluate the clinical efficacy of topiramate as add-on therapy in the refractory West Syndrome.
METHODS
Nineteen children with refractory infantile spasms were included in this study. Topiramate was given as an initial dose of 25 mg per day in addition to the current antiepileptic drug (s). Dosage was increased by 25 mg every week until spasms were controlled, the maximal tolerable dose was reached, or the maximal dose of 25 mg/kg/day was achieved.
RESULTS
Five (26.3%) subjects became seizure free and 7 (36.8%) achieved seizure frequency reduction more than 50%. No significant side effect of topiramate was noted.
CONCLUSION
Topiramate could be a promising therapy in the treatment of refractory West syndrome.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Short term outcomes of topiramate monotherapy as a first-line treatment in newly diagnosed West syndrome
- A New Approach to the Prophylaxis of Cyclic Vomiting: Topiramate
- Safety and Efficacy of Topiramate Monotherapy in Children with Recent-onset Seizures
- Efficacy and Safety of Topiramate in Refractory Childhood Epilepsy
- Topiramate in Pediatric Subjects with Inadequately Controlled Epilepsy : Open-Label Phase IV Multicenter Trial Korean Pediatric Topiramate Study Group
